ICD 2021: Abrocitinib Looks Promising for Moderate to Severe Atopic Dermatitis
The investigational agent is an oral selective Janus kinase 1 inhibitor.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
The investigational agent is an oral selective Janus kinase 1 inhibitor.
Only registered members have full access to PracticeUpdate content.